Market Research Report
Usher Syndrome - Pipeline Review, H2 2017
|Published by||Global Markets Direct||Product code||410986|
|Published||Content info||39 Pages
|Usher Syndrome - Pipeline Review, H2 2017|
|Published: December 29, 2017||Content info: 39 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Usher Syndrome - Pipeline Review, H2 2017, provides an overview of the Usher Syndrome (Genetic Disorders) pipeline landscape.
Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and an eye disorder called retinitis pigmentosa. Risk factors include retinal degeneration, prolonged, unprotected exposure to sunlight may accelerate vision loss. Treatment includes cochlear implants, hearing aids and Vitamin A supplementation.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Usher Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Usher Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Usher Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Usher Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Usher Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.